Table 2.
Risk factors for virologic failure† in the 148 women given single dose nevirapine and tested for nevirapine resistant HIV-1 by OLA prior to initiation of nevirapine-based antiretroviral therapy.
| Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|
| Factor | Hazard ratio for failure (95% CI) |
P value | Adjusted Hazard Ratio (95% CI) |
P value |
| K103N detected by OLA* | 4.9 (2.6–9.4) | < .001 | - | |
| Y181C detected by OLA* | 6.1 (2.6–14) | < .001 | - | |
| G190A detected by OLA* | 2.8 (1.5–5.3) | .001 | - | |
| ≥ 1 NVP-resistance mutations (K103N, Y181C and/or G190A) by OLA |
3.8 (2.1–6.8) | < .001 | 2.5 (1.3–4.5) | .004 |
| ≥ 2 NVP-resistance mutations (K103N, Y181C and/or G190A) by OLA * |
5.6 (2.9–11) | < .001 | - | |
| Plasma HIV-1 RNA | - | |||
| - above median (4.58 log10 copies/ml) during pregnancy * |
2.4 (1.3–4.4) | .004 | ||
| - above median (4.77 log10 copies/ml) at initiation of NVP-ART |
2.2 (1.2–4.1) | .01 | 2.4 (1.3–4.5) | .007 |
| CD4 cell count |
- | |||
| - below median (183 cells/uL) during pregnancy* |
2.0 (1.1–3.7) | .02 | ||
| - below median (153 cells/uL) at initiation of NVP-ART |
1.2 (0.65–2.1) | .61 | - | |
| Time from intrapartum single dose nevirapine to antiretroviral therapy initiation ≤ 6 months |
3.4 (1.8–6.3) | < .001 | 3.2 (1.7–6.2) | .001 |
| NNRTI resistance mutations detected 10 days post partum |
1.4 (0.8–2.5) | .28 | ||
†
defined as confirmed plasma HIV-1 RNA >50 copies/mL between 6 and 18 months of ART.
*
Variables not included in the multivariate analysis because of co-linearity with other variables selected in the multivariate analysis